Drugs for Neglected Diseases
Quick facts
Marketed products
- Amphotericin B Deoxycholate · Infectious Diseases
Amphotericin B binds to ergosterol in fungal cell membranes, creating pores that disrupt membrane integrity and cause cell death. - Lopinavir/ritonavir 4:1 · Infectious Disease
Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication. - lopinavir with ritonavir in 1:1 ratio · Infectious Disease
Lopinavir and ritonavir are HIV protease inhibitors that block the viral protease enzyme, preventing the maturation of HIV particles and reducing viral replication.
Phase 3 pipeline
- Ambisome and Paromomycin · Infectious Disease
Ambisome (liposomal amphotericin B) disrupts fungal cell membranes by binding ergosterol, while paromomycin is an aminoglycoside antibiotic that inhibits protein synthesis in parasites. - Ambisome + Miltefosine · Infectious Disease / Neglected Tropical Diseases
Ambisome (liposomal amphotericin B) disrupts fungal cell membranes while miltefosine inhibits phosphatidylcholine synthesis, together providing synergistic antileishmanial and antifungal activity. - liposomal amphotericin B + miltefosine · Infectious Diseases
Liposomal amphotericin B targets fungal cell membranes, while miltefosine targets fungal cell membranes and inhibits sphingosine N-acyltransferase. - liposomal amphotericin B + paromomycin · Infectious Disease
Liposomal amphotericin B disrupts fungal cell membranes while paromomycin inhibits parasitic protein synthesis, together targeting visceral leishmaniasis parasites. - LPV/RTV pellets and AZT/3TC or ABC/3TC · Infectious Disease / Virology
This combination therapy uses protease inhibitors (lopinavir/ritonavir) to block HIV protease, combined with nucleoside reverse transcriptase inhibitors (AZT/3TC or ABC/3TC) to inhibit viral replication at multiple steps. - matching placebo of emodepside
- Miltefosine and Paromomycin · Infectious Disease / Neglected Tropical Diseases
Miltefosine disrupts parasite cell membranes while paromomycin inhibits protein synthesis, together providing synergistic activity against Leishmania parasites. - SSG and Paromomycin sulphate · Infectious Diseases
SSG and Paromomycin sulphate work by inhibiting protein synthesis in the parasite.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Drugs for Neglected Diseases
What are Drugs for Neglected Diseases's marketed drugs?
Top marketed products include Amphotericin B Deoxycholate, Lopinavir/ritonavir 4:1, lopinavir with ritonavir in 1:1 ratio.
What is Drugs for Neglected Diseases's pipeline?
Drugs for Neglected Diseases has 8 drugs in Phase 3, 2 in Phase 2, 2 in Phase 1. Late-stage candidates include Ambisome and Paromomycin, Ambisome + Miltefosine, liposomal amphotericin B + miltefosine, liposomal amphotericin B + paromomycin.
Related
- Amphotericin B Deoxycholate · Infectious Diseases
- Lopinavir/ritonavir 4:1 · Infectious Disease
- lopinavir with ritonavir in 1:1 ratio · Infectious Disease
- Sector hub: All tracked pharma companies